Effectiveness of a third BNT162b2 mRNA COVID-19 vaccination during pregnancy: a national observational study in Israel

Joshua Guedalia, Michal Lipschuetz, Ronit Calderon-Margalit, Sarah M. Cohen, Debra Goldman-Wohl, Tali Kaminer, Eli Melul, Galit Shefer, Yishai Sompolinsky, Asnat Walfisch, Simcha Yagel and Ofer Beharier ()
Additional contact information
Joshua Guedalia: Faculty of Medicine of the Hebrew University of Jerusalem
Michal Lipschuetz: Faculty of Medicine of the Hebrew University of Jerusalem
Ronit Calderon-Margalit: Faculty of Medicine of the Hebrew University of Jerusalem
Sarah M. Cohen: Faculty of Medicine of the Hebrew University of Jerusalem
Debra Goldman-Wohl: Faculty of Medicine of the Hebrew University of Jerusalem
Tali Kaminer: Israel Ministry of Health
Eli Melul: Israel Ministry of Health
Galit Shefer: Israel Ministry of Health
Yishai Sompolinsky: Faculty of Medicine of the Hebrew University of Jerusalem
Asnat Walfisch: Tel Aviv University
Simcha Yagel: Faculty of Medicine of the Hebrew University of Jerusalem
Ofer Beharier: Faculty of Medicine of the Hebrew University of Jerusalem

Nature Communications, 2022, vol. 13, issue 1, 1-7

Abstract: Abstract The Centers for Disease Control (CDC) recommend a third dose of COVID-19 vaccine for pregnant women, although data regarding effectiveness during pregnancy are lacking. This national, population-based, historical cohort study of pregnant women in Israel, delivering between August 1, 2021 and March 22, 2022, aims to analyze and compare the third and second doses’ vaccine effectiveness in preventing COVID-19-related hospitalizations during pregnancy during two COVID-19 waves (Delta variant in the summer of 2021 and Omicron, BA.1, variant in the winter of 2022). Time-dependent Cox proportional-hazards regression models estimate the hazard ratios (HR) and 95% confidence intervals (CI) for COVID-related outcomes according to vaccine dose, and vaccine effectiveness as 1-HR. Study includes 82,659 and 33,303 pregnant women from the Delta and Omicron waves, respectively. Compared with the second dose, the third dose effectively prevents overall hospitalizations with SARS-CoV-2 infections, with estimated effectiveness of 92% (95% CI 83–96%) during Delta, and enhances protection against significant disease during Omicron, with effectiveness of 92% (95% CI 26–99%), and 48% (95% CI 37–57%) effectiveness against hospitalization overall. A third dose of the BNT162b2 mRNA COVID-19 vaccine during pregnancy, given at least 5 months after the second vaccine dose, enhances protection against adverse COVID-19-related outcomes.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-34605-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-34605-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-34605-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().